ABSTRACT
Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.
ABSTRACT
BACKGROUND: There is limited epidemiological evidence on Lassa fever in pregnant women with acute gaps on prevalence, infection incidence, and risk factors. Such evidence would facilitate the design of therapeutic and vaccine trials and the design of control programs. Our study sought to address some of these gaps by estimating the seroprevalence and seroconversion risk of Lassa fever in pregnant women. METHODOLOGY/PRINCIPAL FINDINGS: We conducted a prospective hospital-based cohort between February and December 2019 in Edo State, Southern Nigeria, enrolling pregnant women at antenatal clinic and following them up at delivery. Samples were evaluated for IgG antibodies against Lassa virus. The study demonstrates a seroprevalence of Lassa IgG antibodies of 49.6% and a seroconversion risk of 20.8%. Seropositivity was strongly correlated with rodent exposure around homes with an attributable risk proportion of 35%. Seroreversion was also seen with a seroreversion risk of 13.4%. CONCLUSIONS/SIGNIFICANCE: Our study suggests that 50% of pregnant women were at risk of Lassa infection and that 35.0% of infections might be preventable by avoiding rodent exposure and conditions which facilitate infestation and the risk of human-rodent contact. While the evidence on rodent exposure is subjective and further studies are needed to provide a better understanding of the avenues of human-rodent interaction; public health measures to decrease the risk of rodent infestation and the risk of spill over events may be beneficial. With an estimated seroconversion risk of 20.8%, our study suggests an appreciable risk of contracting Lassa fever during pregnancy and while most of these seroconversions may not be new infections, given the high risk of adverse outcomes in pregnancy, it supports the need for preventative and therapeutic options against Lassa fever in pregnancy. The occurrence of seroreversion in our study suggests that the prevalence obtained in this, and other cohorts may be an underestimate of the actual proportion of women of childbearing age who present at pregnancy with prior LASV exposure. Additionally, the occurrence of both seroconversion and seroreversion in this cohort suggests that these parameters would need to be considered for the development of Lassa vaccine efficacy, effectiveness, and utility models.
Subject(s)
Lassa Fever , Lassa virus , Pregnancy , Animals , Humans , Female , Nigeria/epidemiology , Seroepidemiologic Studies , Pregnant Women , Cohort Studies , Prospective Studies , Rodentia , Hospitals , Immunoglobulin GABSTRACT
Data on mpox in pregnancy are currently limited. Historically, only 65 cases in pregnancy have been reported globally since mpox was discovered in 1958. This includes 59 cases in the current outbreak. Vertical transmission was confirmed in one patient. Pregnant women are at high risk of severe disease owing to immunological and hormonal changes that increase susceptibility to infections in pregnancy. African women appear to be at higher risk of mpox infection and adverse outcomes in pregnancy for epidemiological and immunologic reasons, in addition to the background high rates of adverse feto-maternal outcomes in the region. This risk is potentially heightened during the COVID-19 pandemic due to the possibility of mpox virus exportation/importation as a result of the lifting of movement restrictions and trans-border travels between countries affected by the current outbreak. Furthermore, coinfection with mpox and COVID-19 in pregnancy is possible, and the clinical features of both conditions may overlap. Challenges of diagnosis and management of mpox in pregnancy in Africa include patients concealing their travel history from healthcare providers and absconding from/evading isolation after diagnosis, shortage of personal protective equipment and polymerase chain reaction testing facilities for diagnosis, vaccine hesitancy/resistance, and poor disease notification systems. There is a need for local, regional and global support to strengthen the capacity of African countries to address these challenges and potentially reduce the disease burden among pregnant women in the continent.
Subject(s)
Mpox (monkeypox) , Pregnancy Complications, Infectious , Female , Humans , Pregnancy , Africa/epidemiology , COVID-19 , Mpox (monkeypox)/epidemiology , Pandemics/prevention & control , Risk Management , Pregnancy Complications, Infectious/epidemiologyABSTRACT
BACKGROUND: Evidence from previous studies suggest that Lassa fever, a viral haemorrhagic fever endemic to West Africa has high case fatalities, particularly in pregnancy. While there have been remarkable innovations in vaccine development, with some Lassa vaccines undergoing early clinical trials. An understanding of Lassa antibody kinetics and immune responses will support vaccine design and development. However, there is currently no evidence on the antibody kinetics of Lassa (LASV) in pregnancy. Our study sought to estimate the efficiency of transplacental transfer of LASV IgG antibodies from the mother to the child. METHODOLOGY/PRINCIPAL FINDINGS: The study made use of data from a prospective hospital-based cohort of pregnant women enrolled at the antenatal clinic and followed up at delivery between February and December 2019. Blood samples from mother-child pairs were evaluated for antibodies against Lassa virus. The study demonstrates a transplacental transfer of LASV IgG of 75.3% [60.0-94.0%], with a significant positive correlation between maternal and cord concentrations and a good level of agreement. The study also suggests that transfer may be more variable in women with 'de novo' antibodies compared to those with pre-existing antibodies. CONCLUSIONS/SIGNIFICANCE: The study shows that maternal antibody levels play an important role in determining transfer efficiency of Lassa antibodies to the new-born; and while the evidence is preliminary, the study also suggests that transfer efficiency may be less stable in acute or recent infection, as such timing of vaccination before pregnancy, that is in women of childbearing age may be more appropriate for protection of both pregnant women and their neonates.
Subject(s)
Lassa Fever , Pregnant Women , Infant, Newborn , Humans , Female , Pregnancy , Nigeria/epidemiology , Immunoglobulin G , Cohort Studies , Prospective Studies , Lassa Fever/epidemiology , Lassa virus , Antibodies, ViralABSTRACT
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a relatively new disease with high morbidity and mortality. Information about the prevalence of infections in pregnancy could help identify herd immunity, project epidemics, and decide policy guidelines. OBJECTIVES: The aim of this study was to determine the infection susceptibility risk of COVID-19 in pregnancy, to determine the prevalence of COVID-19 antibodies (IgG & IgM), and to evaluate the determinants of COVID-19 antibody positivity in pregnancy. MATERIALS AND METHODS: This was an analytical cross-sectional study involving 258 consenting pregnant women recruited at Irrua Specialist Teaching Hospital, Edo State, Nigeria. Of these, 179 participants were recruited from the antenatal clinic, and 79 from the gynecology emergency unit. A structured questionnaire was administered at baseline. Venous blood was obtained at enrolment to test for total antibodies using ELISA. A nasopharyngeal swab was simultaneously obtained for COVID-19 PCR for all participants. Umbilical cord blood was taken after delivery in those who had positive serology. Socio-demographic variables and clinical presentation of respondents were considered as exposure variables, and this was cross-tabulated with outcome variables in bivariate analysis using chi-square with a level of significance at a P-value less than 0.05. Variables in bivariate analysis of chi-square that have a P-value less than 0.2 were entered into a logistic regression using multivariate logistic models. RESULTS: The study detected active COVID-19 infections among 7.4% (19/258) of the study participants. The study demonstrated a seroprevalence of COVID-19 antibodies in 62.4% (161/258) of the participants at recruitment and showed a strong correlation between working in the healthcare setting and living in an urban environment. Our study also reported 5.3% (8/152) of cord blood antibody positivity among study participants. The concentration of maternal immunoglobulin strongly and positively correlated with cord blood seropositivity. CONCLUSION: Prevalence estimates are an underestimate of the actual proportion of pregnant women with prior COVID-19 exposure as observed in the study discrepancy of confirmed PCR infection and evidence of previous infection from serology. The study also highlighted a low efficiency of placental transfer of COVID-19 antibodies at birth among those who were seropositive at baseline and showed that maternal antibody levels play an important role in determining the efficiency of placenta transfer of COVID-19 antibodies in pregnancy.
ABSTRACT
In pregnancy, early signs and symptoms of urinary tract infection, including cystitis or pyelonephritis, may overlap with pregnancy symptoms, making early detection challenging. Compounding this challenge is when it presents itself in resource-poor settings for several factors, including poverty, poor access to healthcare care, inadequate diagnostic facilities, low availability of insurance, education, and cultural limitations. In this case report, we present a case of a 33-year-old G3P2 with pyelonephritis in pregnancy that was compounded by issues related to access to care in resource-limited settings. Although this case was handled in a resource-poor country, fighting to improve access to better health care, the term "underserved" is not exclusive to such a place. Therefore, we reviewed some basic guidelines for managing pyelonephritis in pregnancy and the obstacles in most underprivileged populations.
ABSTRACT
Lassa fever is a viral hemorrhagic fever treated with supportive care and the broad-spectrum antiviral drug ribavirin. The pathophysiology, especially the role of hyperinflammation, of this disease is unknown. We report successful remission of complicated Lassa fever in 2 patients in Nigeria who received the antiinflammatory agent dexamethasone and standard ribavirin.
Subject(s)
Lassa Fever , Antiviral Agents/therapeutic use , Dexamethasone/therapeutic use , Humans , Lassa Fever/diagnosis , Lassa Fever/drug therapy , Lassa virus/genetics , Ribavirin/therapeutic useABSTRACT
BACKGROUND: Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago-the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent. However, a significant amount of work now needs to be undertaken to ensure that future trials for LF can be conducted consistently and reliably to facilitate the efficient generation of evidence. METHODOLOGY: We convened a consultation group to establish the position of clinicians and researchers on the core components of future trials. A Core Eligibility Criteria (CEC), Core Case Definition (CCD), Core Outcome Set (COS) and Core Data Variables (CDV) were developed through the process of a multi-stakeholder consultation that took place using a modified-Delphi methodology. RESULTS: A consensus position was achieved for each aspect of the framework, which accounts for the inclusion of pregnant women and children in future LF clinical trials. The framework consists of 8 core criteria, as well as additional considerations for trial protocols. CONCLUSIONS: This project represents the first step towards delineating the clinical development pathway for new Lassa fever therapeutics, following a period of 40 years without advancement. Future planned projects will bolster the work initiated here to continue the advancement of LF clinical research through a regionally-centred, collaborative methodology, with the aim of delineating a clear pathway through which LF clinical trials can progress efficiently and ensure sustainable investments are made in research capacity at a regional level.
Subject(s)
Antiviral Agents/pharmacology , Clinical Trials, Phase III as Topic/methods , Drug Development/methods , Lassa Fever/drug therapy , Drug Discovery/methods , Humans , Lassa virus/drug effects , Research Design , Surveys and QuestionnairesABSTRACT
The postpartum period is a critical time to address the high unmet needs of family planning and reduce the risks associated with closely spaced pregnancies. Unintended pregnancies immediately following childbirth are associated with increased maternal mortality, morbidity, and poor pregnancy outcomes. Adoption of postpartum family planning is a cost-effective way that would reduce maternal and child morbidity and mortality. This study aimed to establish the prevalence, the clients' sociodemographic factors, and health care workers' influences on modern contraceptive uptake amongst postpartum women at Irrua Specialist Teaching Hospital (ISTH), Irrua. This descriptive cross-sectional study was carried out amongst postpartum mothers attending maternal and child health clinics in ISTH, Irrua, Edo State, Nigeria. The selection of participants was by simple random sampling technique. All consented participants selected through simple random sampling were administered questionnaires, and completed ones were coded and analysed while the level of significance was set at 5%. In this study, over 90% of the women were aware of a method of modern contraception. However, this did not translate to increased contraceptive uptake as only 17.8% of the respondents were currently on a method of postpartum contraception. The statistically significant sociodemographic factors influencing the utilization of modern contraceptives by postpartum women, as seen in this study, were: Age (p <0.001), level of education (p <0.001), religion (p=0.048), and parity (p=0.010). The women who have higher educational status, higher parity, and adequate information provided by healthcare providers were more likely to use at least a method of modern contraceptive postpartum. The uptake of modern contraceptives amongst postpartum women was low in this study. Strengthening family planning counseling services during prenatal care and emphasizing the girl child education, provision of adequate information by healthcare providers on the need for postpartum contraception could enhance modern contraceptive use for postpartum women.